Chinese medicine enterprise or missing the overdue tide of medicines of patent hundred billion

Chinese medicine enterprise or missing the overdue tide of medicines of patent hundred billion
Chinese the intersection of foreign-investment enterprise and the intersection of association and medicines develop and develop the trade committee (RDPAC) " the intersection of pharmacy and the intersection of enterprise and the intersection of quality and system survey and study the project " the report reveal " in the intersection of China and first copy that Guangzhou release a few days ago, because of lacking incentive policies such as the lever of price,etc., the medicine enterprise lacks and invests motive force to the medicines quality management system. And statistics reveal, patent medicine of hundred billion dollars in the world will be overdue in 2010, it is exactly the great opportunity marching into world of Chinese medicine enterprise, but because the management system of quality has not been integrated with the international standard yet, has made a lot of Chinese enterprises probably let slip a golden opportunity. Through investigating 13 pharmacy enterprise, RDPAC report point out current the intersection of medicines and the intersection of price control and frame and the intersection of person who call for bid and medical policy fully consider most people have usable basic demand the most of medicine, but not fully considered enterprises are used for raising problems such as research and development capital source, monitoring and medical information service cost of bad reaction of the quality of medicines,etc.. "The government is issuing the policy and controlling the medicine price empty and high constantly, but neglect the empty and low situation of the medicine price. A lot of medicines although low priced quality can't be ensured. " The biography reputation of minister of market department of Limited Company of traditional Chinese medicines Luo Fushan Zheng in Guangdong is said frankly. The economic affairs director Chen Yi of RDPAC hygiene say, " the incentive policy of the government is essential for guiding the sound development of the pharmacy trade " . For instance Japan, in order to encourage enterprises to formulate new medicine, has increased multiple indexes such as innovating, validity in the new medicine pricing system. Japanese Government's the intersection of price markup and proportion to innovation raise 70%-120% for 2008 to from 40% for 2002, the average input of research and development of medicine enterprise that Japan ranks the top ten rises to 20.9% from 13.8% of the sales amount too in the same term. The statistical data reveal, the whole world loses patent protection of medicines with 139 billion dollars by 2012, this will be that China pharmacy enterprise move towards going on in the international market " First imitative " With the good chance to do brands well and model. Chen Yi thinks, the Chinese medicines price has been already extremely competitive, but because the management system of quality has not been integrated with the international standard yet, make a lot of Chinese enterprises difficult and enter this kind of organizations paying attention to the cost performance very much such as WHO,etc. to purchase in the catalogue. "Set up the intersection of quality and management system that in line with international standards, have an opportunity, move towards world share these enormous cake only. " (Lu ZhiLin)

|